Indeed, in an HFD + DM model of NASH in C57BL6/J mice, administration of a CCN2 neutralizing resulted in reduced levels of fibrosis and expression of fibrosis-related proteins and signaling pathways [73]. This evidence concerns the gene CCN2 and metabolic dysfunction-associated steatohepatitis.